Pharmacokinetic and Pharmacodynamic Evaluation of QRL-101 in a Randomized, Placebo-Controlled, Double-Blind, Single Dose Phase 1 Study in Amyotrophic Lateral Sclerosis Patients

The primary objective of this study is to explore the pharmacokinetic/pharmacodynamic (**PK/PD**) relationship of QRL-101 in individuals diagnosed with **Amyotrophic lateral sclerosis (ALS)**. Understanding the PK/PD relationship is clinically significant as it provides insights into the drug's absorption, distribution, metabolism, and excretion, as well as its pharmacological effects, which are crucial for optimizing therapeutic efficacy and safety in ALS patients.

The clinical trial involves participants diagnosed with **Amyotrophic lateral sclerosis (ALS)**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed as a **randomized**, **placebo-controlled**, **double-blind**, single-dose, Phase 1 study aimed at exploring the pharmacokinetic/pharmacodynamic (PK/PD) relationship of QRL-101 in individuals diagnosed with **amyotrophic lateral sclerosis (ALS)**. The trial is scheduled to commence recruitment on November 8, 2024, and is expected to conclude by March 25, 2025. The study will involve a series of structured visits, beginning with an inclusion visit where participants will undergo screening to confirm eligibility based on predefined criteria. This initial visit will ensure that only suitable candidates are enrolled in the trial.

Following the inclusion visit, participants will be randomly assigned to receive either the investigational product or a placebo, with neither the participants nor the investigators aware of the group assignments, maintaining the double-blind nature of the study. The trial will include follow-up visits to monitor the participants' response to the treatment, assess safety, and collect data on the PK/PD relationship of the drug. These visits are crucial for evaluating the primary and secondary endpoints of the study, although specific endpoints are not detailed in the available data.

The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted to gather comprehensive data on the investigational product's effects. The expected duration of participant involvement will span from the initial screening to the end-of-study visit, aligning with the overall trial timeline. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with study protocols, or withdraw consent. The trial's design and procedures are structured to ensure rigorous evaluation of QRL-101's potential therapeutic benefits for individuals living with ALS.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on November 8, 2024, with an estimated end date of March 25, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the treatment's impact on the specified medical condition, with results contributing to the understanding of the treatment's effectiveness in a controlled setting.